Eli Lilly & Co. LLY
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Eli Lilly & Co. (LLY) Business Model and Operations Summary
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Key Insights
Eli Lilly & Co. (LLY) Core Market Data and Business Metrics
Latest Closing Price
$805.23Market Cap
$722.16 BillionPrice-Earnings Ratio
68.76Total Outstanding Shares
947.99 Million SharesTotal Employees
47,000Dividend
$1.50 Per Share QuarterlyIPO Date
July 9, 1970SIC Description
Pharmaceutical PreparationsPrimary Exchange
New York Stock ExchangeHeadquarters
Lilly Corporate Ctr, Indianapolis, IN, 46285
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $8.82 Billion |
| Exchange Gains/Losses | $-296.70 Million |
| Net Cash Flow From Operating Activities | $8.82 Billion |
| Net Cash Flow From Investing Activities | $-9.30 Billion |
| Net Cash Flow From Financing Activities, Continuing | $1.23 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-9.30 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $10.59 Billion |
| Income/Loss From Continuing Operations Before Tax | $12.68 Billion |
| Costs And Expenses | $32.36 Billion |
| Operating Expenses | $23.94 Billion |
| Income Tax Expense/Benefit, Deferred | $-2.68 Billion |
| Diluted Average Shares | $904.06 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $10.60 Billion |
| Other Comprehensive Income/Loss Attributable To Parent | $5.10 Million |
| Other Comprehensive Income/Loss | $10.60 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $10.60 Billion |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Wages | $2.09 Billion |
| Current Liabilities | $28.38 Billion |
| Noncurrent Liabilities | $36.07 Billion |
| Equity Attributable To Noncontrolling Interest | $79.50 Million |
| Other Non-current Liabilities | $6.59 Billion |
| Liabilities And Equity | $78.71 Billion |
Historical Dividends
Current dividend: $1.50 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Dec 9, 2024 | Mar 10, 2025 | Feb 14, 2025 | $1.5 | Quarterly |
| Oct 28, 2024 | Dec 10, 2024 | Nov 15, 2024 | $1.3 | Quarterly |
| Jun 24, 2024 | Sep 10, 2024 | Aug 15, 2024 | $1.3 | Quarterly |
| May 6, 2024 | Jun 10, 2024 | May 16, 2024 | $1.3 | Quarterly |
| Dec 8, 2023 | Mar 8, 2024 | Feb 15, 2024 | $1.3 | Quarterly |
| Nov 1, 2023 | Dec 8, 2023 | Nov 15, 2023 | $1.13 | Quarterly |